Frontlight ResearchEarly access
What researchers published on Haemophilia
8,357 papers, newest first.
Showing 20 of 370
Trial resultImmunogenicity, safety, and efficacy of rurioctocog alfa pegol in previously untreated patients with severe hemophilia A.Research and practice in thrombosis and haemostasis
In plain wordsRead moreRead the paper on PubMedTrial resultDenecimig (Mim8) prophylaxis in children with hemophilia A with or without factor VIII inhibitors.Research and practice in thrombosis and haemostasis
In plain wordsRead moreRead the paper on PubMedRandomised trialDenecimig (Mim8) prophylaxis over 52 weeks in adolescents and adults with hemophilia A: FRONTIER2 extension study.Research and practice in thrombosis and haemostasis
In plain wordsRead moreRead the paper on PubMedTrial resultSubcutaneous MG1113 in severe hemophilia A and B: phase 1b study for safety, pharmacokinetics, and pharmacodynamics.Research and practice in thrombosis and haemostasis
In plain wordsRead moreRead the paper on PubMedTrial resultFactor IX Padua AAV gene therapy in adolescents with hemophilia B: a phase 1 trial.Nature medicine
In plain wordsRead moreRead the paper on PubMedTrial resultCoagulation potential of concomitant factor VIII administration in people with hemophilia A receiving emicizumab prophylaxis (CAGUYAMA study): a multicenter, open-label, nonrandomized clinical trial.Research and practice in thrombosis and haemostasis
In plain wordsRead moreRead the paper on PubMedTrial resultProspective collection of bleeding rate and factor usage in participants with hemophilia A and B in a noninvestigational product study.Research and practice in thrombosis and haemostasis
In plain wordsRead moreRead the paper on PubMedTrial resultDenecimig (Mim8) prophylaxis once every 2 weeks for hemophilia A with or without inhibitors: 26-week results from FRONTIER4.Blood advances
In plain wordsRead moreRead the paper on PubMedRandomised trialConcizumab in patients with hemophilia A or B without inhibitors: 56-week cutoff results of the phase 3 explorer8 study.Blood advances
In plain wordsRead moreRead the paper on PubMedTrial resultF8 Genotype and Immune Tolerance Induction Outcome in People with Hemophilia A and Inhibitors: A Systematic Review and Meta-Analysis.Thrombosis and haemostasis
In plain wordsRead moreRead the paper on PubMedTrial resultManagement of breakthrough bleeds and surgical procedures in participants with hemophilia A or B without inhibitors receiving marstacimab prophylaxis in the phase 3 BASIS study.Journal of thrombosis and haemostasis : JTH
In plain wordsRead moreRead the paper on PubMedTrial resultDurability of efficacy, safety, and quality of life 5 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A: final phase 3 GENEr8-1 trial results.Research and practice in thrombosis and haemostasis
In plain wordsRead moreRead the paper on PubMedRandomised trialMim8 Bispecific Antibody Prophylaxis in Hemophilia A with or without Inhibitors.The New England journal of medicine
In plain wordsRead moreRead the paper on PubMedTrial resultFinal Analysis of the Phase 1/2 Trial of Valoctocogene Roxaparvovec for Severe Haemophilia A.Haemophilia : the official journal of the World Federation of Hemophilia
In plain wordsRead moreRead the paper on PubMedTrial resultA New Risk-Based Scoring Approach to Individualize Prophylaxis in Patients with Hemophilia A: Results from the PREDICT Study.Advances in therapy
In plain wordsRead moreRead the paper on PubMedTrial resultPhase 1 pilot study for hemophilia-A: AAV8 vector with prophylactic tacrolimus-glucocorticoid achieves therapeutic FVIII activity.Signal transduction and targeted therapy
In plain wordsRead moreRead the paper on PubMedTrial resultA Psychometric Analysis of the Haemophilia Quality of Life Questionnaire for Adults Physical Health Subscale and Total Scores: Data From the Phase 3 XTEND-1 Trial in Patients With Severe Haemophilia A.Haemophilia : the official journal of the World Federation of Hemophilia
In plain wordsRead moreRead the paper on PubMedTrial resultSafety, efficacy, and patient-reported outcomes 6 years after fidanacogene elaparvovec in adults with hemophilia B.Blood advances
In plain wordsRead moreRead the paper on PubMedTrial resultNXTAGE: a phase 1/2 study of NXT007 to assess safety, pharmacokinetics, and efficacy in hemophilia A without inhibitors.Blood
In plain wordsRead moreRead the paper on PubMedTrial resultA specific FX activator for bleeding treatment in hemophilia with inhibitors: multicenter, open-label, phase 1/2 trials.Blood advances
In plain wordsRead moreRead the paper on PubMed